The antitumoral effect of SRF on human colon adenocarcinoma HCT15 xenografts.

SCID female mice were implanted with 1×10⁷ HCT15 human colon adenocarcinoma cells. The treatment started when tumor size attained a 100–200 mm³ or larger. Animals were treated intraperitoneally (i.p.) with 20 mg/kg/dose SRF in final dosing formulation or a 0.9% saline vehicle. Compound was given to tumor-bearing mice on days 1, 4, and 7 after staging, and tumor mass [(length×width²)/2] was determined once a three days for 9 days. Three tumors were observed at different time points. Error bars represent standard error of the mean (n = 3). The data were analyzed by a one-sided Student’s t test, and values of P<0.05 were considered to be significant. *P<0.05 versus vehicle control.